2026年3月25日 美国东部时间上午10:38 / 福克斯新闻
一群跨党派参议员正在重新提出一项法案，将许多美国患者的胰岛素费用每月上限设为35美元——即《2026年胰岛素法案》（INSULIN Act），这一此前停滞的推动行动重新获得了动力。
该法案由新罕布什尔州民主党参议员 Jeanne Shaheen、缅因州共和党参议员 Susan Collins、佐治亚州民主党参议员 Raphael Warnock 和路易斯安那州共和党参议员 John Kennedy 共同提出。法案将禁止团体和个人健康计划对部分胰岛素产品征收免赔额，并且从2027年计划年度开始，30天的供应量收费不得超过35美元。
从2028年开始，患者只需支付35美元或谈判后净价的25%中的较低者。
国会已于2022年规定了仅适用于医疗保险的35美元上限，而唐纳德·特朗普总统长期以来降低处方药成本的议程，在2026年中期选举前为这一努力提供了一定动力。由于共和党在参议院仅以微弱优势（53-47），Collins 的席位可能成为民主党翻牌的目标。
参议院在医疗保健悬崖临近之际悄悄推进两党奥巴马医改修复方案
缅因州共和党参议员 Susan Collins 正协助领导将美国人胰岛素费用每月上限设为35美元的努力。(Tom Williams/CQ-Roll Call, Inc via Getty Images)
“我们是参议院糖尿病核心小组的长期主席，我们的首要任务之一是让胰岛素更实惠，”Collins 在上周的参议院听证会上表示。
“我们的《胰岛素法案》将为商业保险患者设定自付费用上限，打击商业药房福利管理者，并确保患者从他们谈判达成的节省中受益，同时鼓励生物类似药竞争以降低标价。”
该法案于2023年首次提出，在 Kennedy 和 Warnock 的推动下进行了修改，纳入了即使对未参保者也能提供有上限胰岛素价格的相关内容。
“我们的法案还包括帮助未参保美国人获得负担得起的胰岛素的条款，”Collins 继续说道。”就在本周，我会见了一位年轻女性，几年前，因为她买不起，不得不延长胰岛素使用时间，减少剂量，结果最终住进了医院。”
记者观察：共和党在中期选举前以”和解2.0计划”瞄准可负担性
链接：https://www.foxnews.com/video/6373494993112
这一问题与特朗普2024年总统竞选誓言一致。特朗普已宣布其他降低处方药价格的举措，包括去年5月签署的关于其”最惠国”（MNF）政策的行政命令，以对那些不为美国人提供世界最低药品价格的大型制药公司采取行动。
特朗普的政策下令：”美国人不应被迫为其他发达国家的低成本处方药和生物制剂提供补贴，却在美国为同样产品支付过高费用。因此，美国人必须能够获得这些产品的最惠国价格。”
“我的政府将立即采取行动结束全球搭便车行为，如果制药商未能向美国消费者提供最惠国最低价格，我的政府将采取更积极的行动。”
随后，在今年12月，特朗普宣布与九家大型制药公司达成协议，根据最惠国政策降低美国人的药品价格，包括在特朗普的新处方药门户网站 TrumpRx 上直接向消费者提供最低定价。
共和党必须在中期选举前为新的”大而美法案”加速削减成本，资深众议院共和党人警告
TrumpRX 网站上显示礼来公司的赖脯胰岛素售价为25美元。
新罕布什尔州民主党参议员 Janine Shaheen 去年3月宣布不会寻求连任。(Nathan Posner/Anadolu via Getty Images)
Collins 和 Shaheen 的立法还将为未参保者提供有限的胰岛素价格上限——据报道，这一问题是由两党小组中的 Warnock 和 Kennedy 推动的——在10个州创建一个五年试点项目，帮助未参保患者每月以不超过35美元的价格获得胰岛素。
“我们已经将医疗保险参保者的胰岛素费用每月上限设为35美元——我们计划下周提出的这项新《胰岛素法案》将解决儿童、成人和未参保人群的胰岛素负担能力问题，”Shaheen 在一份声明中表示。
“它将像医疗保险条款一样，将雇主和私人保险覆盖的胰岛素费用上限设为每月35美元，创建一个试点项目，为未参保糖尿病患者提供每月35美元的胰岛素，这是帮助面临经济压力的美国家庭的直接方式，从长远来看也将使人们更健康。”
特朗普的处方药计划承诺节省费用，但经济学家看到隐藏的权衡
链接：https://www.foxnews.com/video/6388925766112
虽然 Collins 可能需要该法案来实现她2026年中期选举的希望，但 Shaheen 正在参议院的最后一年任期中。
“我真的希望能够在离开参议院时认为我们帮助解决了很多美国人的胰岛素费用问题：这是最昂贵的慢性病，”Shaheen 告诉 Semafor，同时指出特朗普的价格上限议程。
“这是他应该支持的，因为这关乎可负担性。”
可负担性一直是民主党中期选举的关键词，但共和党人和特朗普则辩称，这只是民主党在乔·拜登前总统任期多年通胀后才提出的问题。
特朗普终结拜登的药品价格噩梦——美国人通过 TrumpRX 获得真正救济
路易斯安那州共和党参议员 John Kennedy 是推动《2026年胰岛素法案》将未参保者胰岛素成本降低的两党参议院小组的成员之一。(Anna Moneymaker / POOL / AFP)
该法案授权2027财年拨款1亿美元用于削减成本，并将”可负担”胰岛素定义为每月供应的自付费用不超过35美元。
Collins 将这项措施描述为对患者因药物成本被迫减少用量以维持生命的回应。
“我听到了太多来自缅因州和全国各地的故事，人们因为成本问题被迫减少胰岛素用量，这简直不可接受，”她告诉 Semafor。
除了消费者价格上限外，该法案还试图通过针对药房福利管理者的做法并鼓励生物类似药和仿制药的更多竞争来降低基础成本。它还下令进行一项联邦研究，调查胰岛素产品推向市场的延迟以及生物类似药采用的障碍。
点击此处下载福克斯新闻应用程序
该提案现在面临更严峻的政治考验：赢得参议院领导层的支持，并在今年晚些时候找到一条必须通过的立法途径。但在多年的失败尝试后，支持者表示他们终于有了一个可能推进的两党框架。
Eric Mack 是福克斯新闻数字版报道突发新闻的撰稿人。
Bipartisan Senate bill to cap insulin for Americans at $35 has new momentum
March 25, 2026 10:38am EDT / Fox News
A bipartisan group of senators is resurfacing legislation to cap many American patients’ insulin costs at $35 a month — the INSULIN Act of 2026 — reviving a push that previously stalled.
The bill, co-authored by Sens. Jeanne Shaheen, D-N.H., Susan Collins, R-Maine, Raphael Warnock, D-Ga., and John Kennedy, R-La., would bar group and individual health plans from imposing deductibles on selected insulin products and could not charge more than $35 for a 30-day supply starting in plan year 2027.
Beginning in 2028, patients would pay the lesser of $35 or 25% of the negotiated net price.
Congress had already mandated a Medicare-only cap of $35 in 2022, and President Donald Trump’s long-running agenda to lower prescription medicine costs gives the effort some momentum before the 2026 midterms, where Collins’ seat could be targeted for a Democrat flip amid the very narrow Republican Senate majority (53-47).
SENATE QUIETLY WORKS ON BIPARTISAN OBAMACARE FIX AS HEALTHCARE CLIFF NEARS
Sen. Susan Collins, R-Maine, is helping to lead the effort to cap insulin costs on Americans at $35 per month.(Tom Williams/CQ-Roll Call, Inc via Getty Images)
“We are the long-time chairs of the Senate Diabetes Caucus, and one of our top priorities is to make insulin more affordable,” Collins said in a Senate hearing last week.
“Our INSULIN Act would impose out-of-pocket limits for patients with commercial insurance, tackle commercial pharmacy benefit managers, and ensure that patients are the ones who are benefiting from the savings that they negotiate, and encourage biosimilar competition in order to lower list prices.”
The bill, first introduced in 2023, has been reworked at Kennedy and Warnock’s urging to include some work to provide capped insulin prices even for the uninsured.
“Our bill also includes provisions to help uninsured Americans access affordable insulin,” Collins continued. “Just this week, I met with a young woman who, a few years ago, ended up in the hospital because she was stretching out her insulin, not taking as much as she was prescribed, because she simply couldn’t afford the cost.”
REPORTER’S NOTEBOOK: GOP TARGETS AFFORDABILITY WITH RECONCILIATION 2.0 PLAN AHEAD OF MIDTERMS
https://www.foxnews.com/video/6373494993112
The issue aligns with a 2024 Trump presidential campaign vow. Trump has already announced other initiatives to lower prescription drug prices, including an executive order last May on his “Most Favored Nation” (MNF) policy to take action on Big Pharma companies that are not offering the world’s lowest price on drugs to Americans.
“Americans should not be forced to subsidize low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States,” Trump’s policy ordered. “Americans must therefore have access to the most-favored-nation price for these products.”
“My Administration will take immediate steps to end global freeloading and, should drug manufacturers fail to offer American consumers the most-favored-nation’s lowest price, my Administration will take additional aggressive action.”
Then, this December, Trump announced agreements with nine Big Pharma companies to lower prices on Americans under the MFN policy, including offering direct to the consumer lowest pricing on TrumpRx, the president’s new prescription drug portal.
GOP MUST RACE FOR NEW ‘BIG, BEAUTIFUL BILL’ TO SLASH COSTS BEFORE MIDTERMS, TOP HOUSE REPUBLICANS WARN
TrumpRX lists Insulin Lispro from Eli Lilly for $25.
Sen. Janine Shaheen, D-N.H., announced last March that she would not be running for re-election.(Nathan Posner/Anadolu via Getty Images)
Collin and Shaheen’s legislation would also offer a limited cap on insulin for the uninsured — an issue reportedly driven by Warnock and Kennedy in the bipartisan group — creating a five-year pilot in 10 states to help uninsured patients get insulin for no more than $35 a month.
“We have already capped insulin for Medicare enrollees at $35 a month — this new INSULIN Act, which we plan to introduce next [this] week, will address insulin affordability for children, adults and those who are uninsured,” Shaheen said in a statement.
“It will do, as the Medicare provision does, cap the cost of employer and private insurance coverage of insulin at $35 a month, create a pilot program to provide $35 a month insulin for uninsured diabetes patients, and it is a direct way to help American families facing economic pressures, and will make people healthier in the long run.”
TRUMP’S RX PLAN PROMISES SAVINGS, BUT ECONOMISTS SEE A HIDDEN TRADE-OFF
https://www.foxnews.com/video/6388925766112
While Collins might need the bill for her 2026 midterm election hopes, Shaheen is serving out her final year in the Senate.
“I would really like to be able to leave the Senate thinking that we had helped to address insulin costs for a lot of Americans: This is the most expensive chronic disease,” Shaheen told Semafor, noting Trump’s agenda for capping prices.
“This is something that he should support, because it is affordability.”
Affordability has been the Democrats’ buzzword for the midterms, but Republicans and Trump have argued it has only been an issue Democrats have made after years of inflation under former President Joe Biden.
TRUMP ENDS BIDEN’S DRUG PRICE NIGHTMARE — AMERICANS GET REAL RELIEF WITH TRUMPRX
Sen. John Kennedy, R-La., was a part of the bipartisan Senate group pushing the INSULIN Act of 2026 to include provisions to lower insulin costs for the uninsured, too.(Anna Moneymaker / POOL / AFP)
The bill authorizes $100 million for fiscal 2027 for cost-cutting and defines “affordable” insulin as out-of-pocket costs of no more than $35 for a one-month supply.
Collins framed the measure as a response to patients rationing medicine they need to survive.
“I have heard far too many stories from people in Maine and across the country who have been forced to ration their insulin because of the cost, and that is simply unacceptable,” she told Semafor.
Beyond the consumer cap, the bill also tries to lower underlying costs by targeting pharmacy benefit manager practices and encouraging more competition from biosimilars and generics. It orders a federal study on delays in bringing insulin products to market and barriers to biosimilar uptake.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The proposal now faces the harder political test: winning buy-in from Senate leadership and finding a path to must-pass legislation later this year. But after years of failed starts, backers say they finally have a bipartisan framework that could move.
Eric Mack is a writer for Fox News Digital covering breaking news.
发表回复